UAB is the only institution in Alabama chosen to date to participate in the TAPUR Study to help further understand targeted therapies in patients with advanced cancers.
This active drug-delivery system addresses the limitations seen for the anti-cancer drug BA-TPQ — poor solubility and low bioavailability.
Five faculty projects were recently funded through an AMC21 initiative giving NIH-funded investigators incentive to submit a second R01.
This is the first demonstration of donor microbes persisting in the recipient following fecal transplant, a finding made possible by a novel method to “fingerprint” individual strains of bacteria.
Michael Birrer, a leading medical oncologist at Harvard University, will take the reins as the new director of the UAB Comprehensive Cancer Center, succeeding the retiring Edward Partridge.
The new UAB Breast Cancer Survivorship Clinic provides breast cancer patients extended follow-up care, helping them adjust to physical and emotional changes after treatment.
The UAB Cancer Center offers patients with advanced and rare cancer, including those with any stage of pancreatic and brain cancer, the opportunity to have no-cost tumor profiling, and patients may be matched with an appropriate clinical trial or recommend use of an FDA-approved drug.
The annual symposium May 15 will provide help and support for cancer patients and survivors.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
UAB announces a partnership with Guideway Care to expand the reach of UAB’s proven cancer navigation program, Patient Care Connect, to patients nationally.
Page 1 of 10